Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer

Access Course

 

Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

 

This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.

 

The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.

 

Learning Objectives:

  • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs alone or in combination with other cancer immunotherapies in the management of advanced lung cancers
  • Have increased knowlege regarding the impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting

 

Approximate Time to Complete: 45 minutes

 

Credit Available: Dec. 26, 2019 - Dec. 26, 2020

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

 

 

 

View Guidelines Here.

View On-demand Webinar Here.

Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.75
Accreditation Council for Pharmacy Education
CEU: 0.08
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.75